Original Article

Randomized, Double-Blind, Placebo- Controlled Trial of Coenzyme Q10 in Isolated Systolic Hypertension

Authors: BRIANT E. BURKE MD, ROGER NEUENSCHWANDER MD, RICHARD D. OLSON PhD

Abstract

AbstractBackground.Increasing numbers of the adult population are using alternative or complementary health resources in the treatment of chronic medical conditions. Systemic hypertension affects more than 50 million adults and is one of the most common risk factors for cardiovascular morbidity and mortality. This study evaluates the antihypertensive effectiveness of oral coenzyme Q10 (CoQ), an over-the-counter nutritional supplement, in a cohort of 46 men and 37 women with isolated systolic hypertension. Methods.We conducted a 12-week randomized, double-blind, placebo-controlled trial with twice daily administration of 60 mg of oral CoQ and determination of plasma CoQ levels before and after the 12 weeks of treatment. Results.The mean reduction in systolic blood pressure of the CoQ-treated group was 17.8 ± 7.3 mm Hg (mean ± SEM). None of the patients exhibited orthostatic blood pressure changes. Conclusions.Our results suggest CoQ may be safely offered to hypertensive patients as an alternative treatment option.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References